NASDAQ:BIAF bioAffinity Technologies (BIAF) Stock Price, News & Analysis $0.25 +0.00 (+1.16%) Closing price 04:00 PM EasternExtended Trading$0.25 -0.01 (-2.06%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About bioAffinity Technologies Stock (NASDAQ:BIAF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BIAF alerts:Sign Up Key Stats Today's Range$0.25▼$0.2650-Day Range$0.23▼$0.3752-Week Range$0.16▼$2.26Volume172,691 shsAverage Volume6.57 million shsMarket Capitalization$7.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas. Read More bioAffinity Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreBIAF MarketRank™: bioAffinity Technologies scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for bioAffinity Technologies.Read more about bioAffinity Technologies' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of bioAffinity Technologies is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bioAffinity Technologies is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiobioAffinity Technologies has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about bioAffinity Technologies' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.49% of the float of bioAffinity Technologies has been sold short.Short Interest Ratio / Days to CoverbioAffinity Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bioAffinity Technologies has recently decreased by 11.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldbioAffinity Technologies does not currently pay a dividend.Dividend GrowthbioAffinity Technologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.49% of the float of bioAffinity Technologies has been sold short.Short Interest Ratio / Days to CoverbioAffinity Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bioAffinity Technologies has recently decreased by 11.02%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for bioAffinity Technologies this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders16.93% of the stock of bioAffinity Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.64% of the stock of bioAffinity Technologies is held by institutions.Read more about bioAffinity Technologies' insider trading history. Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIAF Stock News HeadlinesbioAffinity Technologies Inc News (BIAF) - Investing.comAugust 23 at 10:01 PM | investing.combioAffinity Technologies Appoints New Board MembersAugust 18, 2025 | tipranks.comHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."August 26 at 2:00 AM | Brownstone Research (Ad)bioAffinity Technologies Appoints New Members to Board of DirectorsAugust 18, 2025 | businesswire.combioAffinity Technologies Secures $1.2M Through Private PlacementAugust 15, 2025 | msn.combioAffinity Technologies Sees Surge in CyPath® Lung Test SalesAugust 14, 2025 | msn.combioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross ProceedsAugust 14, 2025 | businesswire.comBioAffinity Technologies announces surge in CyPath Lung salesAugust 13, 2025 | msn.comSee More Headlines BIAF Stock Analysis - Frequently Asked Questions How have BIAF shares performed this year? bioAffinity Technologies' stock was trading at $0.91 on January 1st, 2025. Since then, BIAF shares have decreased by 72.3% and is now trading at $0.2522. How were bioAffinity Technologies' earnings last quarter? bioAffinity Technologies, Inc. (NASDAQ:BIAF) released its quarterly earnings data on Thursday, August, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.03. The company had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.51 million. bioAffinity Technologies had a negative trailing twelve-month return on equity of 845.68% and a negative net margin of 152.16%. When did bioAffinity Technologies IPO? bioAffinity Technologies (BIAF) raised $8 million in an initial public offering (IPO) on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager. How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of bioAffinity Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Lowe's Companies (LOW), Meta Platforms (META), Costco Wholesale (COST), Intel (INTC), AIM ImmunoTech (AIM), Alnylam Pharmaceuticals (ALNY) and Ambrx Biopharma (AMAM). Company Calendar Last Earnings8/14/2025Today8/26/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolNASDAQ:BIAF CIK1712762 Webwww.bioaffinitytech.com Phone210-698-5334FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.04 million Net Margins-152.16% Pretax Margin-151.64% Return on Equity-845.68% Return on Assets-181.92% Debt Debt-to-Equity Ratio0.27 Current Ratio0.64 Quick Ratio0.63 Sales & Book Value Annual Sales$9.36 million Price / Sales0.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book1.48Miscellaneous Outstanding Shares28,470,000Free Float23,649,000Market Cap$7.18 million OptionableNot Optionable Beta2.53 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:BIAF) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access